Amedeo Smart

Free Medical Literature Service

 

Amedeo

Obstructive Lung Diseases
  Free Subscription

Articles published in
Eur Respir J
    December 2024
  1. GUO Y, Donnelly LE
    Identification of an emphysema-specific ATII cell: a step towards understanding impaired lung regeneration in COPD?
    Eur Respir J. 2024;64:2401741.
    >> Share

  2. PIZZICHINI MMM, Pizzichini E
    Is asthma remission an important clinical outcome in asthma management?
    Eur Respir J. 2024;64:2401908.
    >> Share

  3. OKTELIK FB, Benamar M
    Glycerolipids disrupt regulatory T-cells in asthma.
    Eur Respir J. 2024;64:2401386.
    >> Share

  4. BODDULURI S, Nakhmani A, Kizhakke Puliyakote AS, Reinhardt JM, et al
    Airway tapering in COPD.
    Eur Respir J. 2024;64:2400191.
    >> Share

  5. MAURAT E, Raasch K, Leipold AM, Henrot P, et al
    A novel in vitro tubular model to recapitulate features of distal airways: the bronchioid.
    Eur Respir J. 2024;64:2400562.
    >> Share

    November 2024
  6. CHAN AHY, De Keyser HH, Horne R, Szefler SJ, et al
    Defining adherence phenotype and endotypes to personalise asthma management.
    Eur Respir J. 2024 Nov 27:2401357. doi: 10.1183/13993003.01357-2024.
    >> Share

  7. GUO R, Wat D, Ho S, Lam M, et al
    Cardiovascular Benefits and Safety Profile of Macrolide Maintenance Therapy in Patients with Bronchiectasis.
    Eur Respir J. 2024 Nov 27:2401574. doi: 10.1183/13993003.01574-2024.
    >> Share

  8. KHALEVA E, Brightling C, Eiwegger T, Altraja A, et al
    Patient-centred composite scores as tools for assesment of response to biological therapy for paediatric and adult severe asthma.
    Eur Respir J. 2024 Nov 7:2400691. doi: 10.1183/13993003.00691-2024.
    >> Share

  9. CRINER GJ, Gayen S, Zantah M, Dominguez Castillo E, et al
    Clinical review of non-invasive ventilation.
    Eur Respir J. 2024;64:2400396.
    >> Share

  10. POLVERINO F, Woodruff PG
    Radiomultiomics: pioneering precision medicine for severe asthma.
    Eur Respir J. 2024;64:2401639.
    >> Share

  11. TIEW PY, Leung JM, Mac Aogain M, Johal P, et al
    Residential exposure to Aspergillus spp. is associated with exacerbations in COPD.
    Eur Respir J. 2024;64:2400907.
    >> Share

    October 2024
  12. CHALMERS JD, Mall MA, Chotirmall SH, O'Donnell AE, et al
    Targeting neutrophil serine proteases in bronchiectasis.
    Eur Respir J. 2024 Oct 28:2401050. doi: 10.1183/13993003.01050-2024.
    >> Share

  13. HAMADA Y, Thomas D, Harvey ES, Stevens S, et al
    Distinct trajectories of treatment response to mepolizumab toward remission in patients with severe eosinophilic asthma.
    Eur Respir J. 2024 Oct 10:2400782. doi: 10.1183/13993003.00782-2024.
    >> Share

  14. KERMANI NZ, Chung KF, Macis G, Santini G, et al
    Radiomultiomics: quantitative CT clusters of severe asthma associated with multi-omics.
    Eur Respir J. 2024 Oct 10:2400207. doi: 10.1183/13993003.00207-2024.
    >> Share

  15. ROJAS-QUINTERO J, Ochsner SA, Lee HS, Cong C, et al
    Skewed adaptive immune responses are involved in AATD emphysema.
    Eur Respir J. 2024 Oct 10:2400839. doi: 10.1183/13993003.00839-2024.
    >> Share

  16. MCSORLEY HJ
    RIPK2 inhibition gets the NOD for asthma.
    Eur Respir J. 2024;64:2401372.
    >> Share

  17. HOEPER MM
    Selexipag: still looking for its place.
    Eur Respir J. 2024;64:2401560.
    >> Share

  18. CABRERA LOPEZ C, Figueira-Goncalves JM
    Previous exacerbations in newly diagnosed COPD patients: do they matter?
    Eur Respir J. 2024;64:2401019.
    >> Share

  19. HALPIN DMG, Healey H, Skinner D, Carter V, et al
    Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.
    Eur Respir J. 2024;64:2302240.
    >> Share

    September 2024
  20. WECHSLER ME, Brusselle G, Virchow JC, Bourdin A, et al
    Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
    Eur Respir J. 2024 Sep 26:2400316. doi: 10.1183/13993003.00316-2024.
    >> Share

  21. ZHU Z, Shibata R, Hoffman KL, Cormier J, et al
    Integrated nasopharyngeal airway metagenome and asthma genetic risk endotyping of severe bronchiolitis in infancy and risk of childhood asthma.
    Eur Respir J. 2024 Sep 26:2401130. doi: 10.1183/13993003.01130-2024.
    >> Share

  22. GIBSON PG, McDonald VM
    Integrating hot topics and implementation of treatable traits in asthma.
    Eur Respir J. 2024 Sep 10:2400861. doi: 10.1183/13993003.00861-2024.
    >> Share

  23. CHALMERS JD, Shteinberg M, Mall MA, O'Donnell AE, et al
    Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF(R), a Phase II randomised, double-blind, placebo-controlled, dose-finding study.
    Eur Respir J. 2024 Sep 10:2401551. doi: 10.1183/13993003.01551-2024.
    >> Share

  24. LAHOUSSE L
    Overweight and dysanapsis in childhood asthma.
    Eur Respir J. 2024;64:2401164.
    >> Share

  25. MAKRINIOTI H, Fainardi V, Bonnelykke K, Custovic A, et al
    European Respiratory Society statement on preschool wheezing disorders: updated definitions, knowledge gaps and proposed future research directions.
    Eur Respir J. 2024;64:2400624.
    >> Share

  26. BACKMAN H
    10 pack-years of smoking: not the magic number for COPD risk and prognosis.
    Eur Respir J. 2024;64:2401230.
    >> Share

  27. WENZEL SE
    Allergen challenge, eosinophils and the long road to asthma endotypes.
    Eur Respir J. 2024;64:2401316.
    >> Share

  28. COLAK Y, Lokke A, Marott JL, Lange P, et al
    Low smoking exposure and development and prognosis of COPD over four decades: a population-based cohort study.
    Eur Respir J. 2024;64:2400314.
    >> Share

  29. MIDDLETON PG, Simmonds NJ
    Reversal of cystic bronchiectasis with elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2024;64:2400929.
    >> Share

  30. YILDIRIM AO, Conlon TM, Adcock IM, Gosens R, et al
    COPD-iNET: a call to the lung community for action to combat the global epidemic of COPD.
    Eur Respir J. 2024;64:2400921.
    >> Share

    August 2024
  31. VERSI A, Azim A, Ivan FX, Abdel-Aziz MI, et al
    Host-microbial interactions differ with age of asthma onset.
    Eur Respir J. 2024 Aug 30:2400428. doi: 10.1183/13993003.00428-2024.
    >> Share

  32. SHLOBIN OA, Adir Y, Barbera JA, Cottin V, et al
    Pulmonary hypertension associated with lung diseases.
    Eur Respir J. 2024 Aug 29:2401200. doi: 10.1183/13993003.01200-2024.
    >> Share

  33. AILI A, Wang Y, Shang Y, Zhang L, et al
    LPG 18:0 is a general biomarker of asthma and inhibits the differentiation and function of regulatory T cells.
    Eur Respir J. 2024 Aug 15:2301752. doi: 10.1183/13993003.01752-2023.
    >> Share

  34. HU Y, Hu Q, Ansari M, Riemondy K, et al
    Airway derived emphysema-specific alveolar type II cells exhibit impaired regenerative potential in COPD.
    Eur Respir J. 2024 Aug 15:2302071. doi: 10.1183/13993003.02071-2023.
    >> Share

  35. ABDO M, Pedersen F, Kirsten AM, Trinkmann F, et al
    Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD.
    Eur Respir J. 2024 Aug 15:2400347. doi: 10.1183/13993003.00347-2024.
    >> Share

  36. ALVAREZ-SIMON D, Ait Yahia S, Audousset C, Fanton d'Andon M, et al
    Local Receptor-interacting Protein Kinase 2 inhibition mitigates HDM-induced asthma.
    Eur Respir J. 2024 Aug 8:2302288. doi: 10.1183/13993003.02288-2023.
    >> Share

  37. BLOOM C
    The burden of zoster in asthma: what is left to learn?
    Eur Respir J. 2024;64:2401300.
    >> Share

  38. AL SA'IDI L, Berton DC, Neder JA
    The 2022 ERS/ATS z-score classification to grade airflow obstruction: relationship with exercise outcomes across the spectrum of COPD severity.
    Eur Respir J. 2024;64:2301960.
    >> Share

  39. BROWN JS
    The importance of airway IL-1beta in patients with bronchiectasis.
    Eur Respir J. 2024;64:2400997.
    >> Share

  40. KHURANA S, Georas SN
    Stepping down biologics in asthma: is it time to challenge the status quo?
    Eur Respir J. 2024;64:2401168.
    >> Share

  41. ALIBERTI S, Chalmers JD
    Reply to: Sputum colour matters: haemoptysis in a bronchiectasis registry.
    Eur Respir J. 2024;64:2401390.
    >> Share

  42. YAMAMOTO S, Ishikawa H, Takeda K, Kawashima M, et al
    Sputum colour matters: haemoptysis in a bronchiectasis registry.
    Eur Respir J. 2024;64:2400745.
    >> Share

    July 2024
  43. GAUVREAU GM, Sehmi R, FitzGerald JM, Leigh R, et al
    Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
    Eur Respir J. 2024 Jul 26:2400512. doi: 10.1183/13993003.00512-2024.
    >> Share

  44. WILKINSON A, Woodcock A
    High-quality and low-carbon asthma care go hand in hand.
    Eur Respir J. 2024;64:2400638.
    >> Share

  45. SOUMAGNE T, Degano B
    Real world evidence in asthma: what to expect beyond randomised controlled trials?
    Eur Respir J. 2024;64:2400716.
    >> Share

  46. LU J, Wang Z
    Mendelian randomisation supports no evidence of the association between asthma and coronary heart disease in East Asians.
    Eur Respir J. 2024;64:2400628.
    >> Share


  47. "Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC)." A. Spinou, B. Hererro-Cortina, S. Aliberti, et al. Eur Respir J 2024; 63: 2301689.
    Eur Respir J. 2024;64:2351689.
    >> Share

    June 2024
  48. MORTIMER KJ, Cruz AA, Sepulveda-Pachon IT, Jorga A, et al
    Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.
    Eur Respir J. 2024 Jun 20:2400462. doi: 10.1183/13993003.00462-2024.
    >> Share

  49. STIKKER B, Trap L, Sedaghati-Khayat B, de Bruijn MJW, et al
    Epigenomic partitioning of a polygenic risk score for asthma reveals distinct genetically driven disease pathways.
    Eur Respir J. 2024 Jun 20:2302059. doi: 10.1183/13993003.02059-2023.
    >> Share

  50. SAIKUMAR JAYALATHA AK, Ketelaar ME, Hesse L, Badi YE, et al
    IL-33 induced gene expression in activated Th2 effector cells is dependent on IL-1RL1 haplotype and asthma status.
    Eur Respir J. 2024 Jun 6:2400005. doi: 10.1183/13993003.00005-2024.
    >> Share

  51. VERBANCK S, Eddy RL, McIntosh MJ, Parraga G, et al
    Missing airways, ventilation defects and conductive airway physiology in asthma.
    Eur Respir J. 2024 Jun 6:2400242. doi: 10.1183/13993003.00242-2024.
    >> Share

  52. SOENDERGAARD MB, Bjerrum AS, Rasmussen LM, Lock-Johansson S, et al
    OPTIMAL: Titration of anti-IL5 biologics in severe asthma - An open label randomised controlled trial.
    Eur Respir J. 2024 Jun 6:2400404. doi: 10.1183/13993003.00404-2024.
    >> Share

  53. SPINOU A, Almagro M, Harris B, Boyd J, et al
    Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient survey.
    Eur Respir J. 2024 Jun 6:2301504. doi: 10.1183/13993003.01504-2023.
    >> Share

  54. KOVACS G, Humbert M
    Primum non nocere, secundum cavere, tertium sanare: lessons on the management of pulmonary hypertension associated with COPD.
    Eur Respir J. 2024;63:2400765.
    >> Share

  55. CAI J, Vonder M, Du Y, Pelgrim GJ, et al
    Who is at risk of lung nodules on low-dose CT in a Western country? A population-based approach.
    Eur Respir J. 2024;63:2301736.
    >> Share

  56. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2024;63:2400160.
    >> Share

  57. BEASLEY R, Noble J, Weatherall M
    The evidence base for ICS/formoterol maintenance and reliever therapy in severe asthma.
    Eur Respir J. 2024;63:2400523.
    >> Share

  58. IMTIAZ A, King J, Holmes S, Gupta A, et al
    ChatGPT versus Bing: a clinician assessment of the accuracy of AI platforms when responding to COPD questions.
    Eur Respir J. 2024;63:2400163.
    >> Share

    May 2024
  59. PEREA L, Bottier M, Cant E, Richardson H, et al
    Airway IL-1beta is related to disease severity and mucociliary function in bronchiectasis.
    Eur Respir J. 2024 May 29:2301966. doi: 10.1183/13993003.01966-2023.
    >> Share

  60. KJELDGAARD JENSEN S, Tingskov Pedersen CE, Fischer-Rasmussen K, Elsner Melgaard M, et al
    Genetic predisposition to high BMI increases risk of early life respiratory infections and episodes of severe wheeze and asthma.
    Eur Respir J. 2024 May 29:2400169. doi: 10.1183/13993003.00169-2024.
    >> Share

  61. NATHAN SD, Argula R, Trivieri MG, Aziz S, et al
    Inhaled Treprostinil in Pulmonary Hypertension Associated with COPD: PERFECT study results.
    Eur Respir J. 2024 May 29:2400172. doi: 10.1183/13993003.00172-2024.
    >> Share

  62. CHOI H, McShane PJ, Aliberti S, Chalmers JD, et al
    Bronchiectasis management in adults: state of the art and future directions.
    Eur Respir J. 2024 May 23:2400518. doi: 10.1183/13993003.00518-2024.
    >> Share

  63. LIU T, Prescott WG, Zhou X
    Advances in Non-Type 2 Asthma in the Severe Cases: from molecular insights to novel treatment strategies.
    Eur Respir J. 2024 May 2:2300826. doi: 10.1183/13993003.00826-2023.
    >> Share

  64. ELBEHAIRY AF, Marshall H, Naish JH, Wild JM, et al
    Advances in COPD imaging using CT and MRI: linkage with lung physiology and clinical outcomes.
    Eur Respir J. 2024;63:2301010.
    >> Share

  65. RAMAKRISHNAN S, Montgomery B, Pavord ID
    Blood eosinophils and lung function loss: from passive prediction to active prevention?
    Eur Respir J. 2024;63:2400812.
    >> Share

  66. BUSH A, Randerath W, Roche N
    As needed ICS/formoterol: not all of Europe is equal.
    Eur Respir J. 2024;63:2400408.
    >> Share

  67. HONG YS, Park HY, Ryu S, Shin SH, et al
    The association of blood eosinophil counts and FEV(1) decline: a cohort study.
    Eur Respir J. 2024;63:2301037.
    >> Share

  68. POLVERINO F, Sin DD
    Type 2 airway inflammation in COPD.
    Eur Respir J. 2024;63:2400150.
    >> Share

    April 2024
  69. SPINOU A, Hererro-Cortina B, Aliberti S, Goeminne PC, et al
    Airway clearance management in people with bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
    Eur Respir J. 2024 Apr 12:2301689. doi: 10.1183/13993003.01689-2023.
    >> Share

  70. HATTER L, Holliday M, Eathorne A, Bruce P, et al
    The carbon footprint of as-needed budesonide-formoterol in mild asthma: a post hoc analysis.
    Eur Respir J. 2024 Apr 12:2301705. doi: 10.1183/13993003.01705-2023.
    >> Share

  71. JACKSON DJ, Pelaia G, Emmanuel B, Tran TN, et al
    Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme.
    Eur Respir J. 2024 Apr 4:2301521. doi: 10.1183/13993003.01521-2023.
    >> Share

  72. COTTIN V
    Combined pulmonary fibrosis and emphysema syndrome: the age of majority.
    Eur Respir J. 2024;63:2400353.
    >> Share

  73. KRISHNAN JA, Buhl R
    As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2302308.
    >> Share

  74. PAPI A, Ferreira DS, Tonia T, Schleich F, et al
    Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma?
    Eur Respir J. 2024;63:2400395.
    >> Share


  75. "Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis." M.O. Wielputz and M.A. Mall. Eur Respir J 2024; 63: 2400234.
    Eur Respir J. 2024;63:2450234.
    >> Share

  76. TANG RD, Yue JQ, Guan WJ
    Sputum colour as a simplified effective biomarker for clinical assessment of bronchiectasis.
    Eur Respir J. 2024;63:2400152.
    >> Share

  77. STANESCU C, Talarico R, Weichenthal S, Villeneuve PJ, et al
    Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children.
    Eur Respir J. 2024;63:2301568.
    >> Share

  78. ALIBERTI S, Ringshausen FC, Dhar R, Haworth CS, et al
    Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC).
    Eur Respir J. 2024;63:2301554.
    >> Share

  79. VARRICCHI G, Brightling CE, Grainge C, Lambrecht BN, et al
    Airway remodelling in asthma and the epithelium: on the edge of a new era.
    Eur Respir J. 2024;63:2301619.
    >> Share

  80. BLOOM CI
    Reply: Asthma and cardiovascular disease: the strength of triangulation.
    Eur Respir J. 2024;63:2400554.
    >> Share

  81. TATTERSALL MC, Gangnon RE, Jarjour NN
    Asthma and cardiovascular disease: embracing disease heterogeneity is required.
    Eur Respir J. 2024;63:2400469.
    >> Share


  82. ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024;63:24E6304.
    >> Share

    March 2024
  83. LIU T, Liu S, Rui X, Cao Y, et al
    Gasdermin B, an asthma-susceptibility gene, promotes MAVS-TBK1 signaling and airway inflammation.
    Eur Respir J. 2024 Mar 21:2301232. doi: 10.1183/13993003.01232-2023.
    >> Share

  84. LUO RG, Wu YF, Lu HW, Weng D, et al
    Th2-skewed peripheral T helper cells drives B cells in allergic bronchopulmonary aspergillosis.
    Eur Respir J. 2024 Mar 21:2400386. doi: 10.1183/13993003.00386-2024.
    >> Share

  85. RUSSELL RJ, Boulet LP, Brightling CE, Pavord ID, et al
    The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
    Eur Respir J. 2024 Mar 7:2301397. doi: 10.1183/13993003.01397-2023.
    >> Share

  86. JIN Z, Wang G
    Some future directions for genome-wide association studies of preserved ratio impaired spirometry.
    Eur Respir J. 2024;63:2400142.
    >> Share


  87. "Asthma and incident coronary heart disease: an observational and Mendelian randomisation study." C.A. Valencia-Hernandez, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788.
    Eur Respir J. 2024;63:2351788.
    >> Share


  88. "Aberrant anti-viral response of natural killer cells in severe asthma." J. Devulder, C. Chenivesse, V. Ledroit, et al. Eur Respir J 2020; 55: 1802422.
    Eur Respir J. 2024;63:1852422.
    >> Share

  89. WIELPUTZ MO, Mall MA
    Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
    Eur Respir J. 2024;63:2400234.
    >> Share

  90. BOS S, Murray J, Marchetti M, Cheng GS, et al
    ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults.
    Eur Respir J. 2024;63:2301727.
    >> Share

    February 2024
  91. BHATT SP, Bodduluri S, Nakhmani A
    ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction.
    Eur Respir J. 2024;63:2301910.
    >> Share

  92. STANOJEVIC S, Kaminsky DA, Miller MR, Thompson B, et al
    Reply to: ERS/ATS spirometry interpretation standards: a gap in grading severity of airflow obstruction.
    Eur Respir J. 2024;63:2400055.
    >> Share

  93. WEBB AJ
    "Every beet you take": lowering systolic blood pressure and improving vascular function/exercise capacity via the dietary nitrate-nitrite-NO pathway in patients with COPD.
    Eur Respir J. 2024;63:2302238.
    >> Share

  94. ALASMARI AM, Alsulayyim AS, Alghamdi SM, Philip KEJ, et al
    Oral nitrate supplementation improves cardiovascular risk markers in COPD: ON-BC, a randomised controlled trial.
    Eur Respir J. 2024;63:2202353.
    >> Share

  95. COHEN R, Shteinberg M
    Unravelling the "frequent exacerbator" phenotype in cystic fibrosis.
    Eur Respir J. 2024;63:2400068.
    >> Share

  96. WANG T, Duan W, Jia X, Huang X, et al
    Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study.
    Eur Respir J. 2024;63:2301720.
    >> Share

  97. VERLEDEN SE, Lapperre TS, Snoeckx A, Wen W, et al
    Interalveolar pore morphology in (pre-)COPD stages and associations with small airways.
    Eur Respir J. 2024;63:2302263.
    >> Share


  98. ERJ Podcast February 2024: Beetroot juice and cardiovascular risk in COPD.
    Eur Respir J. 2024;63:24E6302.
    >> Share

    January 2024
  99. YOHANNES AM, Iyer AS, Hoth KF, Dransfield MT, et al
    Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?
    Eur Respir J. 2024;63:2301857.
    >> Share

  100. TAYLOR SJC, Sohanpal R, Steed L, Marshall K, et al
    Reply: Cognitive behavioural therapy sessions approach ineffective for anxiety and depression in COPD: is the door closed for good?
    Eur Respir J. 2024;63:2302149.
    >> Share

  101. HIGBEE DH, Lirio A, Hamilton F, Granell R, et al
    Genome-wide association study of preserved ratio impaired spirometry (PRISm).
    Eur Respir J. 2024;63:2300337.
    >> Share

  102. ZHU Z
    Early-life airway microbiome and childhood asthma development.
    Eur Respir J. 2024;63:2302187.
    >> Share

  103. HOGMAN M, Bowerman C, Chavez L, Dressel H, et al
    ERS technical standard: Global Lung Function Initiative reference values for exhaled nitric oxide fraction (F (ENO(50)) ).
    Eur Respir J. 2024;63:2300370.
    >> Share


  104. ERJ Podcast January 2024: The microbiome in early life and childhood asthma.
    Eur Respir J. 2024;63:24E6301.
    >> Share

    December 2023
  105. SUNDE RB MD PHD, Thorsen J MD PhD, Kim M MSc PhD, Schoos AM MD PhD, et al
    Bacterial Colonization of the Airway in Neonates and Risk of Asthma and Allergy Until Age 18 Years.
    Eur Respir J. 2023 Dec 14:2300471. doi: 10.1183/13993003.00471-2023.
    >> Share

  106. BEASLEY R, Noble J, Weatherall M
    Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Eur Respir J. 2023;62:2301844.
    >> Share

  107. SUISSA S
    Simplifying pharmacotherapy for patients with COPD: a viewpoint.
    Eur Respir J. 2023;62:2301510.
    >> Share

  108. CELLI B, Vestbo J
    Reply: Simplifying pharmacotherapy for patients with COPD: a viewpoint.
    Eur Respir J. 2023;62:2301600.
    >> Share

  109. WECKMANN M, Reddy KD
    Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow.
    Eur Respir J. 2023;62:2301552.
    >> Share

    November 2023
  110. ZHAO A, Gudmundsson E, Mogulkoc N, van Moorsel C, et al
    Mortality surrogates in combined pulmonary fibrosis and emphysema.
    Eur Respir J. 2023 Nov 16:2300127. doi: 10.1183/13993003.00127-2023.
    >> Share

  111. CIVIDINI S, Sinha I, Donegan S, Maden M, et al
    Best step-up treatments for children with uncontrolled asthma: A systematic review and network meta-analysis of individual participant data.
    Eur Respir J. 2023 Nov 9:2301011. doi: 10.1183/13993003.01011-2023.
    >> Share

  112. VALENCIA-HERNANDEZ CA, Del Greco M F, Sundaram V, Portas L, et al
    Asthma and incident coronary heart disease: an observational and Mendelian randomisation study.
    Eur Respir J. 2023 Nov 9:2301788. doi: 10.1183/13993003.01788-2023.
    >> Share

  113. SORIANO JB, Polverino F
    Sex and gender in COPD and asthma.
    Eur Respir J. 2023;62:2301505.
    >> Share

  114. EVANS R, Doe G
    Can the curse of mood disorders in COPD be lifted and enable pulmonary rehabilitation?
    Eur Respir J. 2023;62:2301538.
    >> Share

  115. TAYLOR SJC, Sohanpal R, Steed L, Marshall K, et al
    Tailored psychological intervention for anxiety or depression in COPD (TANDEM): a randomised controlled trial.
    Eur Respir J. 2023;62:2300432.
    >> Share

  116. NEPTUNE ER, Cardoso WV
    Unravelling the expanding role of FGF10 signalling in lung homeostasis and maintenance.
    Eur Respir J. 2023;62:2301691.
    >> Share

  117. MORGAN C, Higbee D
    An attack of asthma is not an attack of the heart: clarifying causal links between asthma and incident coronary heart disease.
    Eur Respir J. 2023;62:2302009.
    >> Share

    October 2023
  118. HADZIC S, Wu CY, Gredic M, Pak O, et al
    Fibroblast growth factor 10 reverses cigarette smoke- and elastase-induced emphysema and pulmonary hypertension in mice.
    Eur Respir J. 2023 Oct 26:2201606. doi: 10.1183/13993003.01606-2022.
    >> Share

  119. MCDOWELL PJ, McDowell R, Busby J, Eastwood MC, et al
    Clinical remission in severe asthma with Biologic Therapy: an analysis from the UK Severe Asthma Registry.
    Eur Respir J. 2023 Oct 19:2300819. doi: 10.1183/13993003.00819-2023.
    >> Share

  120. WANG KCW, Elliot JG, Saglani S, Donovan GM, et al
    The airway smooth muscle layer is structurally abnormal in low birth weight infants - implications for obstructive disease.
    Eur Respir J. 2023 Oct 12:2301176. doi: 10.1183/13993003.01176-2023.
    >> Share

  121. HERRERA-LUIS E, de la Rosa-Baez C, Huntsman S, Eng C, et al
    Novel insights into the whole blood DNA methylome of asthma in ethnically diverse children and youth.
    Eur Respir J. 2023 Oct 6:2300714. doi: 10.1183/13993003.00714-2023.
    >> Share

  122. HERRERO-CORTINA B, Spinou A, Oliveira A, O'Neill B, et al
    Airway clearance techniques and exercise in people with bronchiectasis: two different coins.
    Eur Respir J. 2023;62:2300741.
    >> Share


  123. October Podcast: ERS short guidelines for the use of as-needed ICS/formoterol in mild asthma.
    Eur Respir J. 2023;62:23E6204.
    >> Share

    September 2023
  124. FIOCCHI AG, Phipatanakul W, Zeiger RS, Durrani SR, et al
    Dupilumab leads to better-controlled asthma & quality of life in children: the VOYAGE study.
    Eur Respir J. 2023 Sep 21:2300558. doi: 10.1183/13993003.00558-2023.
    >> Share

  125. PAPI A, Ferreira DS, Agache I, Baraldi E, et al
    European Respiratory Society Short Guidelines for the use of as-needed ICS/formoterol in mild Asthma.
    Eur Respir J. 2023 Sep 7:2300047. doi: 10.1183/13993003.00047-2023.
    >> Share

  126. SINGH D
    GOLD 2023 streamlines pharmacological treatment.
    Eur Respir J. 2023;62:2301335.
    >> Share

  127. FARINHA I, Heaney LG
    Defining trajectory in severe asthma: can it be changed?
    Eur Respir J. 2023;62:2301281.
    >> Share

  128. SUISSA S
    Single-inhaler triple versus dual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety.
    Eur Respir J. 2023;62:2300883.
    >> Share

  129. HIEMSTRA PS, Heijink IH
    Oxidation alters IL-33 function: new insights in the biology of different forms of IL-33 and their relevance for COPD.
    Eur Respir J. 2023;62:2301301.
    >> Share

  130. AGUSTI A, Faner R
    All roads lead to COPD... or not?
    Eur Respir J. 2023;62:2301470.
    >> Share

  131. DIVO MJ, Liu C, Polverino F, Castaldi PJ, et al
    From pre-COPD to COPD: a Simple, Low cost and easy to IMplement (SLIM) risk calculator.
    Eur Respir J. 2023;62:2300806.
    >> Share

  132. STRICKSON S, Houslay KF, Negri VA, Ohne Y, et al
    Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.
    Eur Respir J. 2023;62:2202210.
    >> Share

    August 2023
  133. VON BULOW A, Hansen S, Sandin P, Ernstsson O, et al
    Severe asthma trajectories in adults: findings from the NORDSTAR cohort.
    Eur Respir J. 2023 Aug 24:2202474. doi: 10.1183/13993003.02474-2022.
    >> Share

  134. POWELL WT, Reeves SR
    From small to big, using microRNA profiling to investigate infant origins of childhood asthma.
    Eur Respir J. 2023;62:2301052.
    >> Share

  135. BRACKE KR, Polverino F
    Blunted adaptive immune responses and acute exacerbations of COPD: breaking the code.
    Eur Respir J. 2023;62:2301030.
    >> Share

  136. CHEN J, Wang X, Schmalen A, Haines S, et al
    Antiviral CD8(+) T-cell immune responses are impaired by cigarette smoke and in COPD.
    Eur Respir J. 2023;62:2201374.
    >> Share

  137. LI J, Dell'Aniello S, Ernst P, Suissa S, et al
    Real-world comparative effectiveness of three single-inhaler dual bronchodilators for the treatment of COPD.
    Eur Respir J. 2023;62:2300538.
    >> Share

  138. WIJSENBEEK M, Valenzuela C, Holland A
    Palliative care in COPD and ILD: a call for action.
    Eur Respir J. 2023;62:2301076.
    >> Share

  139. CELLI B, Vestbo J
    Simplifying pharmacotherapy for patients with COPD: a viewpoint.
    Eur Respir J. 2023;62:2300115.
    >> Share

  140. OSADNIK CR, Brighton LJ, Burtin C, Cesari M, et al
    European Respiratory Society statement on frailty in adults with chronic lung disease.
    Eur Respir J. 2023;62:2300442.
    >> Share

  141. JANSSEN DJA, Bajwah S, Boon MH, Coleman C, et al
    European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease.
    Eur Respir J. 2023;62:2202014.
    >> Share


  142. August Podcast: Simplifying pharmacotherapy for patients with COPD.
    Eur Respir J. 2023;62:23E6202.
    >> Share

  143. AMEGADZIE JE, Sadatsafavi M
    A long overdue recognition: COPD as a distinct predictor of cardiovascular disease risk.
    Eur Respir J. 2023;62:2301167.
    >> Share

  144. MACLAGAN LC, Croxford R, Chu A, Sin DD, et al
    Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort.
    Eur Respir J. 2023;62:2202364.
    >> Share


  145. ERJ Podcast August 2024: Titration of anti-IL-5 biologics in severe asthma.
    Eur Respir J. 2024;64:24E6402.
    >> Share

    July 2023
  146. CAZZOLA M, Page CP, Matera MG, Rogliani P, et al
    Revisiting Asthma Pharmacotherapy: Where Do We Stand and Where Do We Want to Go?
    Eur Respir J. 2023 Jul 20:2300700. doi: 10.1183/13993003.00700-2023.
    >> Share

  147. NANZER AM, Taylor V, Hearn AP, Kavanagh JE, et al
    The impact of steroid-sparing biologic therapies on weight loss in obese individuals with severe eosinophilic asthma.
    Eur Respir J. 2023 Jul 20:2300245. doi: 10.1183/13993003.00245-2023.
    >> Share

  148. PICCARI L, Blanco I, Torralba Y, Arismendi E, et al
    Mechanisms of hypoxaemia in severe pulmonary hypertension associated with COPD.
    Eur Respir J. 2023 Jul 6:2300463. doi: 10.1183/13993003.00463-2023.
    >> Share

  149. LEUNG JM, Sin DD
    Predicting steroid responsiveness using airway smooth muscle in COPD: a HISTORIC study.
    Eur Respir J. 2023;62:2300956.
    >> Share

  150. STOLZ D, Papakonstantinou E, Pascarella M, Jahn K, et al
    Airway smooth muscle area to predict steroid responsiveness in COPD patients receiving triple therapy (HISTORIC): a randomised, placebo-controlled, double-blind, investigator-initiated trial.
    Eur Respir J. 2023;62:2300218.
    >> Share


  151. July Podcast: The HISTORIC study.
    Eur Respir J. 2023;62:23E6201.
    >> Share

    June 2023
  152. ZHU Z, Freishtat RJ, Harmon B, Hahn A, et al
    Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study.
    Eur Respir J. 2023 Jun 15:2300502. doi: 10.1183/13993003.00502-2023.
    >> Share

  153. VAN DER VEER T, de Koning Gans JM, Braunstahl GJ, Pieters A, et al
    The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised-controlled trial.
    Eur Respir J. 2023 Jun 1:2300186. doi: 10.1183/13993003.00186-2023.
    >> Share

  154. SORIANO JB, Horner A, Studnicka M, Sin DD, et al
    The GOLD 2023 proposed taxonomy: a new tool to determine COPD etiotypes.
    Eur Respir J. 2023;61:2300466.
    >> Share

  155. LEE H, Shin SH, Park HY, Lim SY, et al
    Can we call all obstructive lung diseases COPD?
    Eur Respir J. 2023;61:2300462.
    >> Share

  156. LEUNG V, Lee C
    Shorter duration of antibiotic therapy for exacerbation of COPD.
    Eur Respir J. 2023;61:2300455.
    >> Share

  157. KHAN J, McCarthy C, Franciosi AN
    Questioning the purpose of annual follow-up spirometry for all patients with COPD.
    Eur Respir J. 2023;61:2300292.
    >> Share

  158. AGUSTI A, Anzueto A, Celli BR, Mortimer K, et al
    GOLD 2023 Executive Summary: responses from the GOLD Scientific Committee.
    Eur Respir J. 2023;61:2300616.
    >> Share

  159. KIRENGA BJ, Alupo P, van Gemert F, Jones R, et al
    Implication of the Global Initiative for Chronic Obstructive Lung Disease 2023 report for resource-limited settings: tracing the G in the GOLD.
    Eur Respir J. 2023;61:2300484.
    >> Share

  160. DUIJTS L
    Prematurity-related chronic respiratory disease across the life course.
    Eur Respir J. 2023;61:2300662.
    >> Share

  161. CHALMERS JD, Aliberti S, Altenburg J, Blasi F, et al
    Transforming clinical research and science in bronchiectasis: EMBARC3, a European Respiratory Society Clinical Research Collaboration.
    Eur Respir J. 2023;61:2300769.
    >> Share

    May 2023
  162. HERRERO-CORTINA B, Lee AL, Oliveira A, O'Neill B, et al
    European Respiratory Society statement on airway clearance techniques in adults with bronchiectasis.
    Eur Respir J. 2023 May 4:2202053. doi: 10.1183/13993003.02053-2022.
    >> Share

  163. SIN DD, Doiron D, Agusti A, Anzueto A, et al
    Air pollution and COPD: GOLD 2023 committee report.
    Eur Respir J. 2023;61:2202469.
    >> Share

  164. GOGALI A, Kostikas K
    Latent COPD: a proposed new term in the disease nomenclature.
    Eur Respir J. 2023;61:2300535.
    >> Share

  165. DICKEY BF, Evans CM
    Towards a better mucolytic.
    Eur Respir J. 2023;61:2300619.
    >> Share

  166. ADDANTE A, Raymond W, Gitlin I, Charbit A, et al
    A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
    Eur Respir J. 2023;61:2202022.
    >> Share

    April 2023
  167. EIWEGGER T, Bendien SA
    Defining the questions to be asked in severe asthma trials: data from the COMSA working group.
    Eur Respir J. 2023;61:2202058.
    >> Share

  168. CATALDO D
    COPD pathophysiology: climbing the waterfall of cell death to find a target.
    Eur Respir J. 2023;61:2300093.
    >> Share

  169. MALL MA, Criner GJ, Miravitlles M, Rowe SM, et al
    Cystic fibrosis transmembrane conductance regulator in COPD: a role in respiratory epithelium and beyond.
    Eur Respir J. 2023;61:2201307.
    >> Share

  170. AGUSTI A, Celli BR, Criner GJ, Halpin D, et al
    Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary.
    Eur Respir J. 2023;61:2300239.
    >> Share

  171. VAN EECKHOUTTE HP, Donovan C, Kim RY, Conlon TM, et al
    RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD.
    Eur Respir J. 2023;61:2201506.
    >> Share

  172. ANANTH S, Hurst JR
    ERJ advances: state of the art in definitions and diagnosis of COPD.
    Eur Respir J. 2023;61:2202318.
    >> Share


  173. April Podcast: Global Initiative for Chronic Obstructive Lung Disease 2023 Report.
    Eur Respir J. 2023;61:23E6104.
    >> Share

  174. POLVERINO F, Sciurba F
    Lung volume reduction in COPD: scope or surgery.
    Eur Respir J. 2023;61:2300353.
    >> Share

  175. BUTTERY SC, Banya W, Bilancia R, Boyd E, et al
    Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial.
    Eur Respir J. 2023;61:2202063.
    >> Share

    March 2023
  176. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
    Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
    Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
    >> Share

  177. YANG MJ, Guo SL, Sin DD
    Reply: Association between triple therapy and major adverse cardiovascular events in COPD patients.
    Eur Respir J. 2023;61:2202332.
    >> Share

  178. ALMAGRO P, Martinez-Camblor P
    Comment on: Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
    Eur Respir J. 2023;61:2202208.
    >> Share

  179. MAHMOUD O, Granell R, Peralta GP, Garcia-Aymerich J, et al
    Early-life and health behaviour influences on lung function in early adulthood.
    Eur Respir J. 2023;61:2001316.
    >> Share

  180. CHARRIOT J, Ahmed E, Bourdin A
    Local targeting of TSLP: feat or defeat.
    Eur Respir J. 2023;61:2202389.
    >> Share

  181. SCHNEIDER S, Poglitsch K, Morgenstern C, Quint T, et al
    Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
    Eur Respir J. 2023;61:2201335.
    >> Share

  182. NOBLE PB, Donovan GM
    If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease.
    Eur Respir J. 2023;61:2202307.
    >> Share

  183. CORREN J, Brightling CE, Boulet LP, Porsbjerg C, et al
    Not just an anti-eosinophil drug: tezepelumab treatment for type 2 asthma and beyond.
    Eur Respir J. 2023;61:2202202.
    >> Share

  184. BOULET LP, Boulay ME, Cote A, FitzGerald JM, et al
    Airway inflammation and hyperresponsiveness in subjects with respiratory symptoms and normal spirometry.
    Eur Respir J. 2023;61:2201194.
    >> Share

    February 2023
  185. GAUVREAU GM, Hohlfeld JM, FitzGerald MJ, Boulet LP, et al
    Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.
    Eur Respir J. 2023 Feb 23:2201193. doi: 10.1183/13993003.01193-2022.
    >> Share

  186. ABDO M, Kirsten AM, von Mutius E, Kopp M, et al
    Minimal Clinically Important Difference for Impulse Oscillometry in Adults with Asthma.
    Eur Respir J. 2023 Feb 9:2201793. doi: 10.1183/13993003.01793-2022.
    >> Share

  187. HE ZF, Zha SS, Pan CX, Zhong NS, et al
    Insights into the clinical outcomes of bronchiectasis.
    Eur Respir J. 2023;61:2202104.
    >> Share

  188. DHAR R, Chalmers JD
    Reply to: Insights into the clinical outcomes of bronchiectasis.
    Eur Respir J. 2023;61:2202224.
    >> Share

  189. REGARD L, Burgel PR, Roche N
    Inhaled therapy, cardiovascular risk and benefit-risk considerations in COPD: innocent until proven guilty, or vice versa?
    Eur Respir J. 2023;61:2202135.
    >> Share

  190. SAVOURE M, Bousquet J, Leynaert B, Renuy A, et al
    Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort.
    Eur Respir J. 2023;61:2200943.
    >> Share

  191. YANG M, Li Y, Jiang Y, Guo S, et al
    Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
    Eur Respir J. 2023;61:2200302.
    >> Share

  192. PEDERSEN ESL, Kuehni CE
    Preventing bronchiolitis among infants with non-pharmaceutical interventions outside pandemics: is it realistic?
    Eur Respir J. 2023;61:2202214.
    >> Share

  193. LENGLART L, Ouldali N, Honeyford K, Bognar Z, et al
    Respective roles of non-pharmaceutical interventions in bronchiolitis outbreaks: an interrupted time-series analysis based on a multinational surveillance system.
    Eur Respir J. 2023;61:2201172.
    >> Share

    January 2023
  194. GAO YH, Zheng HZ, Lu HW, Li YY, et al
    The impact of depression and anxiety on the risk of exacerbation in adults with bronchiectasis: A prospective cohort study.
    Eur Respir J. 2023 Jan 20:2201695. doi: 10.1183/13993003.01695-2022.
    >> Share

  195. POLLOCK J, Chalmers JD
    Aspergillus sensitisation: an underappreciated treatable trait in airway disease.
    Eur Respir J. 2023;61:2202042.
    >> Share

  196. FAWCETT KA
    Seeing the trees for the wood: reducing heterogeneity in genomic studies of asthma.
    Eur Respir J. 2023;61:2201931.
    >> Share

  197. BROWN JS, Hurst JR
    Bronchiectasis in low- and middle-income countries: the importance of the wider view.
    Eur Respir J. 2023;61:2201977.
    >> Share

  198. RATANACHINA J, Amaral AFS, De Matteis S, Lawin H, et al
    Association of respiratory symptoms and lung function with occupation in the multinational Burden of Obstructive Lung Disease (BOLD) study.
    Eur Respir J. 2023;61:2200469.
    >> Share

  199. MILLER MR, Stanojevic S, Kaminsky DA, Thompson BR, et al
    A reply to questions raised about FEV(1)Q and bronchodilator responsiveness.
    Eur Respir J. 2023;61:2202025.
    >> Share

  200. GUAN WJ, Hu PC, Martinez-Garcia MA
    The transcriptomic landscape of diffuse radiological bronchiectasis.
    Eur Respir J. 2023;61:2201733.
    >> Share

    December 2022
  201. DAVIES D, Hyland ME, Lanario JW, Jones RC, et al
    Moving towards patient-centred outcomes: the Severe Asthma Questionnaire.
    Eur Respir J. 2022 Dec 30:2202305. doi: 10.1183/13993003.02305-2022.
    >> Share

  202. RATTU A, Khaleva E, Brightling C, Dahlen SE, et al
    Identifying and appraising outcome measures for severe asthma: a systematic review.
    Eur Respir J. 2022 Dec 22:2201231. doi: 10.1183/13993003.01231-2022.
    >> Share

  203. KOCKS J, van der Molen T, Voorham J, Baldi S, et al
    Development of a tool to detect small airways dysfunction in asthma clinical practice.
    Eur Respir J. 2022 Dec 14:2200558. doi: 10.1183/13993003.00558-2022.
    >> Share

  204. HAHN DL, Webley W
    U-BIOPRED/BIOAIR proteins: inflammation or infection?
    Eur Respir J. 2022;60:2200571.
    >> Share

  205. SPARREMAN MIKUS M, Kolmert J, Andersson LI, Dahlen SE, et al
    Reply: U-BIOPRED/BIOAIR proteins: inflammation or infection?
    Eur Respir J. 2022;60:2201795.
    >> Share

  206. LUCZKA-MAJERUS E, Bonnomet A, Germain A, Lalun N, et al
    Ciliogenesis is intrinsically altered in COPD small airways.
    Eur Respir J. 2022;60:2200791.
    >> Share

  207. MENZIES-GOW A, Gurnell M, Heaney LG, Corren J, et al
    Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study.
    Eur Respir J. 2022;60:2103226.
    >> Share

    November 2022
  208. CHERIAN M, Magner KMA, Whitmore GA, Vandemheen KL, et al
    Patient and physician factors associated with symptomatic undiagnosed asthma or COPD.
    Eur Respir J. 2022 Nov 3. pii: 13993003.01721-2022.
    >> Share

  209. BUSSE WW
    Improving systemic corticosteroid stewardship in asthma.
    Eur Respir J. 2022;60.
    >> Share

  210. PARK JS, Cho YJ, Yun JY, Lee HJ, et al
    Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series.
    Eur Respir J. 2022;60.
    >> Share

  211. PETSKY H
    Randomised controlled trials utilising F ENO to manage asthma: is it time to acknowledge that "one size does not fit all"?
    Eur Respir J. 2022;60.
    >> Share

  212. ROBERTS G
    Is it time to consider allergen immunotherapy earlier in the management of allergic asthma?
    Eur Respir J. 2022;60.
    >> Share

  213. MENDY A, Merianos AL, Mersha TB, Mahabee-Gittens EM, et al
    Blood volatile organic compounds associated with non-reversible and reversible airflow obstruction in US adults.
    Eur Respir J. 2022;60:2201185.
    >> Share

    October 2022
  214. XU K, Diaz AA, Duan F, Lee M, et al
    Bronchial Gene Expression Alterations Associated with Radiographic Bronchiectasis.
    Eur Respir J. 2022 Oct 13. pii: 13993003.00120-2022.
    >> Share

  215. DHAR R, Singh S, Talwar D, Bv MM, et al
    Clinical outcomes of bronchiectasis in India; Data from the EMBARC/Respiratory Research Network of India registry.
    Eur Respir J. 2022 Oct 13. pii: 13993003.00611-2022.
    >> Share

  216. KHALEVA E, Rattu A, Brightling C, Bush A, et al
    Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA).
    Eur Respir J. 2022 Oct 13. pii: 13993003.00606-2022.
    >> Share

  217. POLVERINO F, Marin JM
    The lower respiratory tract: the hot spot for chronic fixed airflow limitation.
    Eur Respir J. 2022;60.
    >> Share

  218. ROMEI C, Castellana R, Conti B, Bemi P, et al
    Quantitative texture-based analysis of pulmonary parenchymal features on chest CT: comparison with densitometric indices and short-term effect of changes in smoking habit.
    Eur Respir J. 2022;60.
    >> Share

  219. HILLER AM, Ekstrom M, Piitulainen E, Lindberg A, et al
    Cancer risk in severe alpha-1-antitrypsin deficiency.
    Eur Respir J. 2022;60.
    >> Share

    September 2022
  220. PERSSON C
    Creola bodies and pathogenesis of childhood asthma.
    Eur Respir J. 2022 Sep 30. pii: 13993003.01204-2022.
    >> Share

  221. COLEMAN C, Khaleva E, Rattu A, Frankemolle B, et al
    Narrative Review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma.
    Eur Respir J. 2022 Sep 14. pii: 13993003.00837-2022.
    >> Share

  222. LIU J, Bowatte G, Pham J, Perret JL, et al
    Pre-pubertal smoke exposure of fathers and increased risk of offspring asthma: a possible transgenerational effect.
    Eur Respir J. 2022 Sep 14. pii: 13993003.00257-2022.
    >> Share

  223. SORIANO JB
    Planetary respiratory health for asthma, rhinoconjunctivitis and eczema.
    Eur Respir J. 2022;60.
    >> Share

  224. CHAN JSK, Murray RB, Price D
    Oral corticosteroids in asthma and beyond: moving forward.
    Eur Respir J. 2022;60.
    >> Share

  225. ZHANG J, Xu H, Qiao D, DeMeo DL, et al
    A polygenic risk score and age of diagnosis of COPD.
    Eur Respir J. 2022;60.
    >> Share

  226. PERREM L, Subbarao P
    Moving the dial on identifying endotypes of asthma from early life.
    Eur Respir J. 2022;60.
    >> Share


  227. "Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma." M.K. Ali, R.Y. Kim, A.C. Brown et al. Eur Respir J 2020; 55: 1901340.
    Eur Respir J. 2022;60.
    >> Share

  228. PAVORD ID
    Case-finding and diagnosis of obstructive airway diseases: the Dragons' Den experience.
    Eur Respir J. 2022;60.
    >> Share

  229. BONADIES L, Papi A, Baraldi E
    Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
    Eur Respir J. 2022;60.
    >> Share

  230. UM-BERGSTROM P, Pourbazargan M, Brundin B, Strom M, et al
    Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.
    Eur Respir J. 2022;60.
    >> Share

    August 2022
  231. CHAN R, Lipworth B
    Interactions between spirometry and oscillometry in patients with moderate to severe asthma.
    Eur Respir J. 2022 Aug 18. pii: 13993003.00543-2022.
    >> Share

  232. LEE S, Prokopenko D, Kelly RS, Lutz S, et al
    Zinc finger protein 33B demonstrates sex-interaction with atopy-related markers in childhood asthma.
    Eur Respir J. 2022 Aug 11. pii: 13993003.00479-2022.
    >> Share

  233. TIEW PY, Narayana JK, Li Quek MS, Ang YY, et al
    Sensitisation to recombinant Aspergillus fumigatus allergens and clinical outcomes in COPD.
    Eur Respir J. 2022 Aug 4. pii: 13993003.00507-2022.
    >> Share

  234. BURGEL PR, Roche N
    Cystic fibrosis transmembrane conductance regulator (CFTR): a missing link between smoking and chronic airway diseases?
    Eur Respir J. 2022;60.
    >> Share

  235. BONDONNO NP, Parmenter BH, Dalgaard F, Murray K, et al
    Flavonoid intakes inversely associate with COPD in smokers.
    Eur Respir J. 2022;60.
    >> Share

  236. SAFERALI A, Qiao D, Kim W, Raraigh K, et al
    C FTR variants are associated with chronic bronchitis in smokers.
    Eur Respir J. 2022;60.
    >> Share

  237. SOUTHWORTH T, Jackson N, Singh D
    Airway immune responses to COVID-19 vaccination in COPD patients and healthy subjects.
    Eur Respir J. 2022;60.
    >> Share

  238. PUTMAN RK, Axelsson GT, Ash SY, Sanders JL, et al
    Interstitial lung abnormalities are associated with decreased mean telomere length.
    Eur Respir J. 2022;60.
    >> Share

    July 2022
  239. PERRET JL, Dharmage SC, Bui DS
    Early life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?
    Eur Respir J. 2022 Jul 26. pii: 13993003.01141-2022.
    >> Share

  240. MCLOUGHLIN RF, Clark VL, Urroz PD, Gibson PG, et al
    Increasing physical activity in severe asthma: a systematic review and meta-analysis.
    Eur Respir J. 2022 Jul 26. pii: 13993003.00546-2022.
    >> Share

  241. VAN MEEL ER, Duijts L
    Reply to: "Early-life respiratory infections and pre-adult asthma: could there be an interaction and differential misclassification?"
    Eur Respir J. 2022 Jul 26. pii: 13993003.01384-2022.
    >> Share

  242. TISI S, Dickson JL, Horst C, Quaife SL, et al
    Detection of COPD in the SUMMIT Study Lung Cancer Screening Cohort using Symptoms and Spirometry.
    Eur Respir J. 2022 Jul 26. pii: 13993003.00795-2022.
    >> Share

  243. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
    Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
    >> Share

  244. REDMOND C, Heaney LG, Chaudhuri R, Jackson DJ, et al
    Benefits of specialist severe asthma management: demographic and geographic disparities.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00660-2022.
    >> Share

  245. HOLMES J, McGarvey LP, Birring SS, Fletcher H, et al
    An observational study to determine the relationship between cough frequency and markers of inflammation in severe asthma.
    Eur Respir J. 2022 Jul 1. pii: 13993003.03205-2021.
    >> Share

  246. SALTER B, Zhao N, Son K, Suray Tan N, et al
    Airway autoantibodies are determinants of asthma severity.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00442-2022.
    >> Share

  247. WURZEL D, Licciardi PV
    Targeted strategies are needed to prevent childhood asthma.
    Eur Respir J. 2022;60.
    >> Share

  248. KAZA N, Lin VY, Stanford D, Hussain SS, et al
    Evaluation of a novel CFTR potentiator in COPD ferrets with acquired CFTR dysfunction.
    Eur Respir J. 2022;60.
    >> Share

  249. WARK PAB
    We need to understand why viral infections lead to acute asthma.
    Eur Respir J. 2022;60.
    >> Share

  250. MATTILA T, Erhola M, Vasankari T, Toppila-Salmi S, et al
    Controlling chronic respiratory diseases in Finland from 1996 to 2018.
    Eur Respir J. 2022;60.
    >> Share

  251. VAN HULST G, Jorssen J, Jacobs N, Henket M, et al
    Reply: Ex vivo SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significance.
    Eur Respir J. 2022;60.
    >> Share

  252. COUILLARD S
    The alarmin(g) effect of interleukin-5 blockade on residual eosinophil function is of clinical consequence.
    Eur Respir J. 2022;60.
    >> Share

  253. MCINNIS MC, Ma J, Karur GR, Houbois C, et al
    Chronic lung allograft dysfunction phenotype and prognosis by machine learning CT analysis.
    Eur Respir J. 2022;60.
    >> Share

    June 2022
  254. SHOEMARK A, Griffin H, Wheway G, Hogg C, et al
    Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.
    Eur Respir J. 2022 Jun 21. pii: 13993003.00176-2022.
    >> Share

  255. CHANG AB, Zacharasiewicz A, Goyal V, Boyd J, et al
    Task Force report: European Respiratory Society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials.
    Eur Respir J. 2022 Jun 21. pii: 13993003.00300-2022.
    >> Share


  256. "International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma." Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek, et al. Eur Respir J 2014; 43: 343-373.
    Eur Respir J. 2022;59.
    >> Share

  257. CAZZOLA M, Martinez-Garcia MA, Matera MG
    Bronchodilators in bronchiectasis: there is light but it is still too dim.
    Eur Respir J. 2022;59.
    >> Share

  258. CHANG AB, Boyd J, Bush A, Hill AT, et al
    International consensus statement on quality standards for managing children/adolescents with bronchiectasis from the ERS CRC Child-BEAR-Net.
    Eur Respir J. 2022;59.
    >> Share

  259. YUGE M, Hori S, Ushida K, Momosaki R, et al
    Karaoke as a feasible alternative therapy to pulmonary rehabilitation for COPD.
    Eur Respir J. 2022;59.
    >> Share

  260. LOKKE A, Kaasgaard M, Andreasson KH, Rasmussen DB, et al
    Reply: The effectiveness of singing versus exercise training.
    Eur Respir J. 2022;59.
    >> Share

  261. VAES AW, Spruit MA, Franssen FME, van 't Hul AJ, et al
    The efficacy of singing versus exercise training: do the data really support the authors' conclusions?
    Eur Respir J. 2022;59.
    >> Share

  262. BATEMAN ED, Price DB, Wang HC, Schonffeldt P, et al
    Reply to: Cause or consequence?
    Eur Respir J. 2022;59.
    >> Share

  263. VOLPE FM
    Cause or consequence?
    Eur Respir J. 2022;59.
    >> Share

  264. CHALMERS JD, Aksamit T, Aliberti S, Dhar R, et al
    World Bronchiectasis Day 2022.
    Eur Respir J. 2022;59.
    >> Share

    May 2022
  265. WOEHLK C, Von Bulow A, Ghanizada M, Baastrup Sondergaard M, et al
    Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.
    Eur Respir J. 2022 May 26. pii: 13993003.00446-2022.
    >> Share

  266. SUN Y, Zhang M, Ou Z, Meng Y, et al
    Indoor microbiome, microbial and plant metabolites, chemical compounds and asthma symptoms in junior high school students: a multicentre association study in Malaysia.
    Eur Respir J. 2022 May 26. pii: 13993003.00260-2022.
    >> Share

  267. HUMBERT M, Bourdin A, Taille C, Kamar D, et al
    Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of pediatric and adult asthmatics.
    Eur Respir J. 2022 May 26. pii: 13993003.03130-2021.
    >> Share

  268. HABENER A, Grychtol R, Gaedcke S, DeLuca D, et al
    IgA(+) memory B cells are significantly increased in patients with asthma and small airways dysfunction.
    Eur Respir J. 2022 May 20. pii: 13993003.02130-2021.
    >> Share

  269. KROES JA, Zielhuis SW, De Jong K, Hashimoto S, et al
    Cumulative Corticosteroid Sparing Effect of Anti-Interleukin-5/5Ra In Eosinophilic Asthma.
    Eur Respir J. 2022 May 20. pii: 13993003.02983-2021.
    >> Share

  270. AZZO L, Ali YS, Vaqar S, Dauriat G, et al
    Severe pulmonary hypertension associated with chronic obstructive pulmonary disease Long-term results of a prospective French multicenter cohort.
    Eur Respir J. 2022 May 20. pii: 13993003.02897-2021.
    >> Share

  271. KOEHLER P, von Stillfried S, Garcia Borrega J, Fuchs F, et al
    Aspergillus tracheobronchitis in COVID-19 patients with acute respiratory distress syndrome: a cohort study.
    Eur Respir J. 2022;59.
    >> Share

  272. MATHIOUDAKIS AG, Abroug F, Agusti A, Ananth S, et al
    ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations.
    Eur Respir J. 2022;59.
    >> Share

  273. GAIETTO K, Han YY, Forno E, Bacharier LB, et al
    Violence-related distress and lung function in two longitudinal studies of youth.
    Eur Respir J. 2022;59.
    >> Share

  274. LATIMER LE, Constantin-Teodosiu D, Popat B, Constantin D, et al
    Whole-body and muscle responses to aerobic exercise training and withdrawal in ageing and COPD.
    Eur Respir J. 2022;59.
    >> Share

  275. SORIANO JB, Hopkinson NS
    Sing out for COPD!
    Eur Respir J. 2022;59.
    >> Share

  276. VESTBO J, Waterer G, Leather D, Crim C, et al
    Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD.
    Eur Respir J. 2022;59.
    >> Share

  277. YUN JH, Lee S, Srinivasa P, Morrow J, et al
    An interferon-inducible signature of airway disease from blood gene expression profiling.
    Eur Respir J. 2022;59.
    >> Share

  278. KAASGAARD M, Rasmussen DB, Andreasson KH, Hilberg O, et al
    Use of Singing for Lung Health as an alternative training modality within pulmonary rehabilitation for COPD: a randomised controlled trial.
    Eur Respir J. 2022;59.
    >> Share

  279. FAIZ A, van den Berge M
    Quality over quantity: the importance of collecting relevant samples to understand complex diseases.
    Eur Respir J. 2022;59.
    >> Share

  280. HIGHAM A, Beech A, Jackson N, Lea S, et al
    Sputum cell counts in COPD patients who use electronic cigarettes.
    Eur Respir J. 2022;59.
    >> Share

  281. XU F, Vasilescu DM, Kinose D, Tanabe N, et al
    The molecular and cellular mechanisms associated with the destruction of terminal bronchioles in COPD.
    Eur Respir J. 2022;59.
    >> Share

    April 2022
  282. RABE KF, Pavord ID, Castro M, Wechsler ME, et al
    Dupilumab efficacy and safety in patients with asthma and blood eosinophils >/=500 cells.microL(-1).
    Eur Respir J. 2022 Apr 29. pii: 13993003.02577-2021.
    >> Share

  283. VAN MEEL ER, Mensink-Bout SM, den Dekker HT, Ahluwalia TS, et al
    Early-life respiratory tract infections and the risk of school-age lower lung function and asthma: a meta-analysis of 150 000 European children.
    Eur Respir J. 2022 Apr 29. pii: 13993003.02395-2021.
    >> Share

  284. MENSINK-BOUT SM, van Meel ER, de Jongste JC, Annesi-Maesano I, et al
    Maternal diet in pregnancy and child's respiratory outcomes: an individual participant data meta-analysis of 18 000 children.
    Eur Respir J. 2022;59.
    >> Share

  285. SKRONSKA-WASEK W, Durlanik S, Le HQ, Schroeder V, et al
    The antimicrobial peptide S100A8/A9 produced by airway epithelium functions as a potent and direct regulator of macrophage phenotype and function.
    Eur Respir J. 2022;59.
    >> Share

  286. SINGH D, Beier J, Astbury C, Belvisi MG, et al
    The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
    Eur Respir J. 2022;59.
    >> Share

    March 2022
  287. THOMAS D, McDonald VM, Pavord ID, Gibson PG, et al
    Asthma remission- what is it and how can it be achieved?
    Eur Respir J. 2022 Mar 31. pii: 13993003.02583-2021.
    >> Share

  288. SCHILDKNECHT K, Winthrop KL, Prevots DR, Blakney R, et al
    Nontuberculous mycobacterial pulmonary disease incidence among elderly patients with bronchiectasis.
    Eur Respir J. 2022 Mar 31. pii: 13993003.00018-2022.
    >> Share

  289. HUYNH C, Whitmore GA, Vandemheen KL, FitzGerald JM, et al
    Derivation and Validation of the UCAP-Q Case-finding Questionnaire to Detect Undiagnosed Asthma and COPD.
    Eur Respir J. 2022 Mar 24. pii: 13993003.03243-2021.
    >> Share

  290. HAN YY, Yan Q, Chen W, Celedon JC, et al
    Child maltreatment, anxiety and depression, and asthma among British adults in the UK Biobank.
    Eur Respir J. 2022 Mar 17. pii: 13993003.03160-2021.
    >> Share

  291. BAL C, Idzko M, Skrgat S, Koch A, et al
    FeNO is associated with disease burden in the German Asthma Net severe asthma cohort.
    Eur Respir J. 2022 Mar 10. pii: 13993003.01233-2021.
    >> Share

  292. KLEIN DK, Silberbrandt A, Frossing L, Hvidtfeldt M, et al
    Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma.
    Eur Respir J. 2022 Mar 2. pii: 13993003.02446-2021.
    >> Share

  293. VONK JM, Roukema J
    Air pollution susceptibility in children with asthma and obesity: tidal volume as key player?
    Eur Respir J. 2022;59.
    >> Share

  294. POLVERINO F
    Adaptive immune responses and protein homeostasis in COPD: the immunoproteasome.
    Eur Respir J. 2022;59.
    >> Share

  295. THAMRIN C, Robinson PD, Farah CS, King GG, et al
    Technical standards for respiratory oscillometry and bronchodilator response cut-offs.
    Eur Respir J. 2022;59.
    >> Share

  296. KAMMERL IE, Hardy S, Flexeder C, Urmann A, et al
    Activation of immune cell proteasomes in peripheral blood of smokers and COPD patients: implications for therapy.
    Eur Respir J. 2022;59.
    >> Share

  297. DAGHER R, Kumar V, Copenhaver AM, Gallagher S, et al
    Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity.
    Eur Respir J. 2022;59.
    >> Share

    February 2022
  298. MAISON N, Omony J, Illi S, Thiele D, et al
    T-high asthma phenotypes across life span.
    Eur Respir J. 2022 Feb 24. pii: 13993003.02288-2021.
    >> Share

  299. ALI GB, Lowe AJ, Perret JL, Walters EH, et al
    Impact of lifetime body mass index trajectories on the incidence and persistence of adult asthma.
    Eur Respir J. 2022 Feb 24. pii: 13993003.02286-2021.
    >> Share

  300. MORTIMER K, Reddel HK, Pitrez PM, Bateman ED, et al
    Asthma management in low- and middle-income countries: case for change.
    Eur Respir J. 2022 Feb 24. pii: 13993003.03179-2021.
    >> Share

  301. MORTIMER K, Lesosky M, Garcia-Marcos L, Innes Asher M, et al
    The burden of asthma, hay fever and eczema in adults in 17 countries: GAN Phase I study.
    Eur Respir J. 2022 Feb 24. pii: 13993003.02865-2021.
    >> Share

  302. MOSLEMI A, Kontogianni K, Brock J, Wood S, et al
    Differentiating COPD and Asthma using Quantitative CT Imaging and Machine Learning.
    Eur Respir J. 2022 Feb 24. pii: 13993003.03078-2021.
    >> Share

  303. LOUIS R, Satia I, Ojanguren I, Schleich F, et al
    European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults.
    Eur Respir J. 2022 Feb 15. pii: 13993003.01585-2021.
    >> Share

  304. SKOV IR, Madsen H, Henriksen DP, Andersen JH, et al
    Low dose oral corticosteroids in asthma associates with increased morbidity and mortality.
    Eur Respir J. 2022 Feb 10. pii: 13993003.03054-2021.
    >> Share

  305. TAYTARD J, Koskas M, Beydon N
    Spirometry forced expiratory time is driven by airflow limitation in asthmatic children.
    Eur Respir J. 2022 Feb 10. pii: 13993003.02620-2021.
    >> Share

  306. GARCIA-MARCOS L, Innes Asher M, Pearce N, Ellwood E, et al
    The burden of asthma, hay fever and eczema in children in 25 countries: GAN Phase I study.
    Eur Respir J. 2022 Feb 10. pii: 13993003.02866-2021.
    >> Share

  307. MARCON A, Locatelli F, Accordini S
    The coexistence of asthma and COPD: some considerations about prevalence and lung function decline.
    Eur Respir J. 2022 Feb 3. pii: 13993003.00096-2022.
    >> Share

  308. KEARNS N, Bruce P, Williams M, Doppen M, et al
    Repeated dose budesonide/formoterol compared to salbutamol in adult asthma: A randomised cross-over trial.
    Eur Respir J. 2022 Feb 3. pii: 13993003.02309-2021.
    >> Share

  309. SEYS SF, Long MB
    The quest for biomarkers in asthma: challenging the T2 versus non-T2 paradigm.
    Eur Respir J. 2022;59.
    >> Share

  310. ZHANG PD, Zhang XR, Zhang A, Li ZH, et al
    Associations of genetic risk and smoking with incident COPD.
    Eur Respir J. 2022;59.
    >> Share

  311. FRANCIOSI AN, Fraughen D, Carroll TP, McElvaney NG, et al
    Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold.
    Eur Respir J. 2022;59.
    >> Share

    January 2022
  312. PARASKAKIS E, Sarikloglou E, Fouzas S, Steiropoulos P, et al
    Improved prediction of asthma exacerbations by measuring distal airway inflammation.
    Eur Respir J. 2022 Jan 27. pii: 13993003.01684-2021.
    >> Share

  313. GAUVREAU GM, Davis BE, Scadding G, Boulet LP, et al
    Allergen Provocation Tests in Respiratory Research: Building on 50 Years of Experience.
    Eur Respir J. 2022 Jan 27. pii: 13993003.02782-2021.
    >> Share

  314. RICCARDI D, Ward JP, Yarova PL, Janssen LJ, et al
    Topical therapy with negative allosteric modulators of the calcium-sensing receptor (calcilytics) for the management of asthma: the beginning of a new era?
    Eur Respir J. 2022 Jan 20. pii: 13993003.02103-2021.
    >> Share

  315. AL-SHAIKHLY T, Murphy RC, Parker A, Lai Y, et al
    Location of eosinophils in the airway wall is critical for specific features of airway hyperresponsiveness and T2 inflammation in asthma.
    Eur Respir J. 2022 Jan 13. pii: 13993003.01865-2021.
    >> Share

  316. PEROTIN JM, Wheway G, Tariq K, Azim A, et al
    Vulnerability to acid reflux of the airway epithelium in severe asthma.
    Eur Respir J. 2022 Jan 7. pii: 13993003.01634-2021.
    >> Share

  317. RAMIS J, Middlewick R, Pappalardo F, Cairns JT, et al
    Lysyl oxidase-like 2 is increased in asthma and contributes to asthmatic airway remodelling.
    Eur Respir J. 2022 Jan 7. pii: 13993003.04361-2020.
    >> Share

  318. COLAK Y, Lange P
    Interpreting blood eosinophil counts in health and obstructive lung disease.
    Eur Respir J. 2022;59.
    >> Share

  319. BENSON VS, Hartl S, Barnes N, Galwey N, et al
    Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.
    Eur Respir J. 2022;59.
    >> Share

    December 2021
  320. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
    Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
    >> Share

  321. PORSBJERG C, Nieto-Fontarigo JJ, Cerps S, Ramu S, et al
    Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02333-2021.
    >> Share

  322. AGARWAL R, Muthu V
    Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02989-2021.
    >> Share

  323. HAVETTE A, Regard L, Roche N, Burgel PR, et al
    Prednisolone plus itraconazole in acute-stage allergic bronchopulmonary aspergillosis complicating asthma: is the benefit worth the risk?
    Eur Respir J. 2021 Dec 9. pii: 13993003.02924-2021.
    >> Share

  324. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
    Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
    Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
    >> Share

  325. GURDENIZ G, Ernst M, Rago D, Kim M, et al
    Neonatal metabolome of cesarean section and risk of childhood asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
    >> Share

  326. RYAN D, Sabroe I
    Identifying and addressing health inequalities in asthma care.
    Eur Respir J. 2021;58.
    >> Share

  327. PAPAIOANNOU AI, Photiades A, Gaga M
    Using placebo-controlled trials to define predictors of future exacerbations in severe asthma patients.
    Eur Respir J. 2021;58.
    >> Share

  328. CHALMERS JD, Keir HR
    Less is more? Antibiotic treatment duration for exacerbations of bronchiectasis.
    Eur Respir J. 2021;58.
    >> Share

  329. KURODA N, Shiroshita A, Tsujimoto Y
    Room for methodological improvement in gait speed study for COPD patients.
    Eur Respir J. 2021;58.
    >> Share

  330. WALSH JA, Barker RE, Kon SSC, Jones SE, et al
    Reply to: Room for methodological improvement in gait speed study for COPD patients.
    Eur Respir J. 2021;58.
    >> Share

  331. LIU S, Lim YH, Pedersen M, Jorgensen JT, et al
    Long-term air pollution and road traffic noise exposure and COPD: the Danish Nurse Cohort.
    Eur Respir J. 2021;58.
    >> Share

  332. HERNANDEZ CORDERO AI, Yang CX, Milne S, Li X, et al
    Epigenetic blood biomarkers of ageing and mortality in COPD.
    Eur Respir J. 2021;58.
    >> Share

  333. BEDI P, Cartlidge MK, Zhang Y, Turnbull K, et al
    Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: a proof-of-concept randomised controlled trial.
    Eur Respir J. 2021;58.
    >> Share

  334. PARK S, Lee S, Kim Y, Cho S, et al
    Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study.
    Eur Respir J. 2021;58.
    >> Share

    November 2021
  335. ABDEL-AZIZ MI, Vijverberg SJH, Neerincx AH, Brinkman P, et al
    A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes.
    Eur Respir J. 2021 Nov 25. pii: 13993003.02603-2021.
    >> Share

  336. REINKE SN, Naz S, Chaleckis R, Gallart-Ayala H, et al
    Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study.
    Eur Respir J. 2021 Nov 25. pii: 13993003.01733-2021.
    >> Share

  337. JAYARAM L, Vandal AC, Chang C, Lewis C, et al
    Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial.
    Eur Respir J. 2021 Nov 18. pii: 13993003.02184-2021.
    >> Share

  338. MIKUS MS, Kolmert J, Andersson LI, Ostling J, et al
    Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.
    Eur Respir J. 2021 Nov 4. pii: 13993003.00142-2021.
    >> Share

  339. STRIDSMAN C, Vanfleteren LEGW, Konradsen JR, Axelsson Fisk S, et al
    Predictors of severe COVID-19 in a registry-based Swedish cohort of patients with COPD.
    Eur Respir J. 2021;58.
    >> Share

  340. OLIVER BG
    Food for thought: why is there more airway smooth muscle in asthma?
    Eur Respir J. 2021;58.
    >> Share

  341. MANNINO DM
    Asthma, COPD and their overlap: coexistence or something more?
    Eur Respir J. 2021;58.
    >> Share

  342. WALSH JA, Barker RE, Kon SSC, Jones SE, et al
    Gait speed and adverse outcomes following hospitalised exacerbation of COPD.
    Eur Respir J. 2021;58.
    >> Share

  343. FINNEGAN SL, Harrison OK, Harmer CJ, Herigstad M, et al
    Breathlessness in COPD: linking symptom clusters with brain activity.
    Eur Respir J. 2021;58.
    >> Share

    October 2021
  344. PIJNENBURG MW, Frey U, De Jongste JC, Saglani S, et al
    Childhood asthma- pathogenesis and phenotypes.
    Eur Respir J. 2021 Oct 28. pii: 13993003.00731-2021.
    >> Share

  345. ELSEY L, Pantin T, Holmes LJ, Tavernier G, et al
    Outcomes over the first two years of treatment with mepolizumab in severe asthma.
    Eur Respir J. 2021 Oct 28. pii: 13993003.01313-2021.
    >> Share

  346. SIBILA O, Laserna E, Shoemark A, Perea L, et al
    Heterogeneity of treatment response in bronchiectasis clinical trials.
    Eur Respir J. 2021 Oct 21. pii: 13993003.00777-2021.
    >> Share

  347. REDDEL HK, Bacharier LB, Bateman ED, Brightling CE, et al
    Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes.
    Eur Respir J. 2021 Oct 19. pii: 13993003.02730-2021.
    >> Share

  348. CHAN R, Misirovs R, Lipworth B
    Repeatability of impulse oscillometry in patients with severe asthma.
    Eur Respir J. 2021 Oct 8. pii: 13993003.01679-2021.
    >> Share

  349. SUN Y, Xia PF, Xie J, Mustieles V, et al
    Association of blood trihalomethane concentrations with asthma in U.S. adolescents: nationally representative cross-sectional study.
    Eur Respir J. 2021 Oct 8. pii: 13993003.01440-2021.
    >> Share

  350. PORSBJERG C, Maitland-van der Zee AH, Brusselle G, Canonica GW, et al
    3TR: a pan-European cross-disease research consortium aimed at improving personalised biological treatment of asthma and COPD.
    Eur Respir J. 2021;58.
    >> Share

  351. CHANG AB, Boyd J, Bush A, Grimwood K, et al
    Children's Bronchiectasis Education Advocacy and Research Network (Child-BEAR-Net): an ERS Clinical Research Collaboration on improving outcomes of children and adolescents with bronchiectasis.
    Eur Respir J. 2021;58.
    >> Share

  352. KEIR HR, Chalmers JD
    IL-6 trans-signalling: how Haemophilus surfs the NET to amplify inflammation in COPD.
    Eur Respir J. 2021;58.
    >> Share

  353. PETOUSI N, Wooden A, Russell REK
    A new piece in the puzzle: the eosinophil and the development of COPD.
    Eur Respir J. 2021;58.
    >> Share

  354. WINSLOW S, Odqvist L, Diver S, Riise R, et al
    Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and Haemophilus infection in COPD.
    Eur Respir J. 2021;58.
    >> Share

  355. PHILIP J, Collins A, Smallwood N, Chang YK, et al
    Referral criteria to palliative care for patients with respiratory disease: a systematic review.
    Eur Respir J. 2021;58.
    >> Share

  356. PARK HY, Chang Y, Kang D, Hong YS, et al
    Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study.
    Eur Respir J. 2021;58.
    >> Share

  357. HIRAI K, Tanaka A, Sato H, Sato Y, et al
    Effect of surgical mask on exercise capacity in COPD: a randomised crossover trial.
    Eur Respir J. 2021;58.
    >> Share

    September 2021
  358. MIURA S, Iwamoto H, Omori K, Yamaguchi K, et al
    Accelerated decline in lung function in adults with a history of remitted childhood asthma.
    Eur Respir J. 2021 Sep 29. pii: 13993003.00305-2021.
    >> Share

  359. BATEMAN ED, Price DB, Wang HC, Khattab A, et al
    Short-acting beta2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study.
    Eur Respir J. 2021 Sep 24. pii: 13993003.01402-2021.
    >> Share

  360. BUSBY J, Matthews JG, Chaudhuri R, Pavord ID, et al
    Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.
    Eur Respir J. 2021 Sep 24. pii: 13993003.00768-2021.
    >> Share

  361. PANAGOU P, Tzilas V, Bouros D
    "Dynamic (C dyn) lung compliance in non-smokers with asthma and fixed, non-reversible airflow obstruction" ERJ 2021 58: 2004400.
    Eur Respir J. 2021 Sep 24. pii: 13993003.02361-2021.
    >> Share

  362. GREDIC M, Wu CY, Hadzic S, Pak O, et al
    Myeloid cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice.
    Eur Respir J. 2021 Sep 2. pii: 13993003.01153-2021.
    >> Share

  363. LOUIS R, Louis G, Bonhomme O
    NOVELTY: a landmark study in phenotyping and endotyping chronic obstructive airway diseases in real clinical practice.
    Eur Respir J. 2021;58.
    >> Share

  364. BAFADHEL M, Barnes N, Bourke SC, Compton C, et al
    A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial.
    Eur Respir J. 2021;58.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016